Containment-Verification Testing For Pharmaceutical Equipment Performance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Containment-Verification Testing For Pharmaceutical Equipment Performance
A Good Practice Guide from the International Society of Pharmaceutical Engineering provides a framework to assess how well pharmaceutical equipment contains hazardous APIs.


Pharmaceutical Technology
Volume 37, Issue 5, pp. s24-s27

Conclusion

Containment-verification testing of equipment and containment systems is an accepted means for evaluating the containment capability of containment systems and processing equipment in the pharmaceutical and biotechnology industries under defined conditions. ISPE’s Good Practice Guide: Assessing the Particulate Containment Performance of Pharmaceutical Equipment describes the methodologies for performing containment verification testing for both FAT and SAT scenarios. The guide specifies a methodology using a surrogate material to verify containment performance by setting a CPT and then performing air and surface sampling as outlined in standard protocols for containment systems. By following the guidelines, users can generate accurate and repeatable data to perform statistical analysis and confirm that airborne-release concentrations will not normally exceed the CPT. >

References>

1. B.D. Naumann and E.V. Sargent, “Setting Occupational Exposure Limits for Pharmaceuticals,” Occup. Med. , 12(1): 67-79 (1997). >

2. OSHA, Sec. II: Ch. 1, “Personal Sampling for Air Contaminants,” in OSHA Technical Manual (OTM) (Washington, DC, June 24, 2008). >

3. OSHA, Sec. II: Ch. 2, “Occupational Skin Exposure V. Wipe Sampling Methodology,” OSHA Technical Manual (OTM) , (Washington, DC, June 24, 2008). >

4. ISPE, Good Practice Guide: Assessing the Particulate Containment Performance of Pharmaceutical Equipment (Second Edition, Tampa, FL, 2012) >

All figures and tables courtesy of the International Society of Pharmaceutical Engineering.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here